MX2023014100A - Variante de fc con afinidad aumentada para los receptores de fc y estabilidad termica mejorada. - Google Patents
Variante de fc con afinidad aumentada para los receptores de fc y estabilidad termica mejorada.Info
- Publication number
- MX2023014100A MX2023014100A MX2023014100A MX2023014100A MX2023014100A MX 2023014100 A MX2023014100 A MX 2023014100A MX 2023014100 A MX2023014100 A MX 2023014100A MX 2023014100 A MX2023014100 A MX 2023014100A MX 2023014100 A MX2023014100 A MX 2023014100A
- Authority
- MX
- Mexico
- Prior art keywords
- domain variants
- receivers
- variant
- thermal stability
- improved thermal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193665P | 2021-05-27 | 2021-05-27 | |
| EP21315127 | 2021-07-15 | ||
| PCT/IB2022/055019 WO2022249146A1 (en) | 2021-05-27 | 2022-05-27 | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014100A true MX2023014100A (es) | 2023-12-11 |
Family
ID=82358573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014100A MX2023014100A (es) | 2021-05-27 | 2022-05-27 | Variante de fc con afinidad aumentada para los receptores de fc y estabilidad termica mejorada. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12297273B2 (enExample) |
| EP (1) | EP4347640A1 (enExample) |
| JP (1) | JP2024522092A (enExample) |
| KR (1) | KR20240015093A (enExample) |
| AU (1) | AU2022282666A1 (enExample) |
| BR (1) | BR112023022584A2 (enExample) |
| CA (1) | CA3216005A1 (enExample) |
| CO (1) | CO2023016432A2 (enExample) |
| IL (1) | IL308733A (enExample) |
| MX (1) | MX2023014100A (enExample) |
| TW (1) | TW202306584A (enExample) |
| WO (1) | WO2022249146A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133427A1 (es) | 2023-07-31 | 2025-09-24 | Sanofi Sa | Anticuerpos anti-gprc5d y composiciones |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7312181B2 (en) | 2005-04-08 | 2007-12-25 | Cropsolution, Inc. | Acylated thiosemicarbazides as herbicides |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| MX2012004029A (es) * | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2013138643A1 (en) * | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| AR103488A1 (es) | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| AR107582A1 (es) * | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| AR108963A1 (es) | 2016-04-13 | 2018-10-17 | Merial Inc | Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| CN108218998A (zh) * | 2017-12-31 | 2018-06-29 | 武汉班科生物技术股份有限公司 | 一种突变型人源IgG的Fc片段及其制备方法与应用 |
| BR112020015006A2 (pt) | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| JP7792330B2 (ja) * | 2019-09-03 | 2025-12-25 | アムジエン・インコーポレーテツド | Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法 |
-
2022
- 2022-05-27 TW TW111119900A patent/TW202306584A/zh unknown
- 2022-05-27 EP EP22726534.5A patent/EP4347640A1/en active Pending
- 2022-05-27 AU AU2022282666A patent/AU2022282666A1/en active Pending
- 2022-05-27 IL IL308733A patent/IL308733A/en unknown
- 2022-05-27 KR KR1020237044602A patent/KR20240015093A/ko active Pending
- 2022-05-27 US US17/826,295 patent/US12297273B2/en active Active
- 2022-05-27 MX MX2023014100A patent/MX2023014100A/es unknown
- 2022-05-27 WO PCT/IB2022/055019 patent/WO2022249146A1/en not_active Ceased
- 2022-05-27 JP JP2023572758A patent/JP2024522092A/ja active Pending
- 2022-05-27 CA CA3216005A patent/CA3216005A1/en active Pending
- 2022-05-27 BR BR112023022584A patent/BR112023022584A2/pt unknown
-
2023
- 2023-11-29 CO CONC2023/0016432A patent/CO2023016432A2/es unknown
-
2025
- 2025-03-26 US US19/091,594 patent/US20250376526A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12297273B2 (en) | 2025-05-13 |
| US20250376526A1 (en) | 2025-12-11 |
| AU2022282666A1 (en) | 2024-01-18 |
| JP2024522092A (ja) | 2024-06-11 |
| EP4347640A1 (en) | 2024-04-10 |
| TW202306584A (zh) | 2023-02-16 |
| WO2022249146A1 (en) | 2022-12-01 |
| KR20240015093A (ko) | 2024-02-02 |
| BR112023022584A2 (pt) | 2024-01-09 |
| US20230077531A1 (en) | 2023-03-16 |
| IL308733A (en) | 2024-01-01 |
| CA3216005A1 (en) | 2022-12-01 |
| CO2023016432A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004145A (es) | Variantes de desoxirribonucleasa (dnasa). | |
| AR120534A1 (es) | Aislados paenibacillus y sus usos | |
| MX2010000944A (es) | Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones. | |
| AR121761A2 (es) | Polipéptidos que presentan actividad de fosfolipasa y polinucleótidos que codifican los mismos | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| ECSP13012869A (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos | |
| UY35596A (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX2019008780A (es) | Composiciones detergentes. | |
| CO2018001420A2 (es) | Biomasa rica en proteína de traustoquitridios, método de cultivo y utilización | |
| MX2014015287A (es) | Derivado del ester del acido heteroarilcarboxilico. | |
| MX2018001706A (es) | Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1). | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| MX2018014043A (es) | Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| MX2019000805A (es) | Variantes de serinproteasa y polinucleotidos que las codifican. | |
| CL2018002430A1 (es) | Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| CO2021016487A2 (es) | Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| AR118493A1 (es) | Métodos para la fabricación de vectores virales recombinantes |